Shares of Canadian cannabis company Tilray Inc. TLRY, +4.27% jumped 5.9% in premarket trade Wednesday, after it swung to a profit in its fiscal fourth quarter. Tilray said it had net income of $33.5 million in the quarter to May 31, or 18 cents a share, after a loss of $84.3 million, or 39 cents a share, in the year-earlier period. Revenue rose to $142.2 million from $113.5 million a year ago. The FactSet consensus was for a loss of 12 cents a share and revenue of $199 million. Revenue was boosted by 36% growth in cannabis revenue to $53.7 million, which included four weeks of contribution from legacy-Tilray, a 10% decline in distribution revenue, net beverage alcohol revenue of $15.9 million following the SweetWater acquisition on November 25, 2020, and wellness revenue of $5.8 million from Manitoba Harvest, the company said in a statement. The company remained loss-making on a full-year basis, recording a loss of $336 million, wider than the loss of $100.8 million posted in fiscal 2020. The loss was driven by $63.6 million in transaction costs, following its merger with Aphria, and $170.5 million of non-cash unrealized loss on convertible bonds. The company has achieved $35 million in synergies on the Aphria deal and expects to reach its goal of about $80 million within 18 months of closing. U.S.-listed shares have gained 54% in the year to date, while the Cannabis ETF THCX, +0.69% has gained 17% to match the S&P 500s SPX, -0.13% gain.

Coronavirus tally: Global cases of COVID-19 top 217 million as study finds Moderna vaccine produced more antibodies than Pfizers

The global tally for the coronavirus-borne illness climbed above 217 million on Tuesday, while the death toll rose to 4.51 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 39 million cases and 638,715 deaths. The daily average of new cases over the past seven days rose to 158,946 as of Monday, up 12% from two weeks ago, according to a New York Times tracker. The daily average for deaths increased to 1,348 up 91% in two weeks, and is now trending above 1,000 for the first time since March, the tracker shows. The daily average for hospitalizations rose to 100,663, up 22% from two weeks ago and continuing to trend at the highest levels since winter. A study comparing individual immune responses to two major COVID-19 vaccines has shown that Modernas undefined created more than double the antibodies than that of Pfizer undefined and BioNTech undefined. The study involving 2,499 Belgian health-care workers who were vaccinated with two doses of either companys vaccine was published on Mondayin the Journal of the American Medical Association. India has the second highest death toll after the U.S. at 438,560 and is third by cases at 32.8 million, the JHU data shows. Brazil has second highest death toll at 579,574 and has 20.8 million cases. In Europe, Russia has 180,009 deaths, followed by the U.K. with 132,808.

Ciara Linnane is MarketWatchs investing- and corporate-news editor. She is based in New York.